Evidence map›Paper›PMID 40236459›Full record

ReviewFrontiers in medicine2025

Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases.

Zhi Guo, Jie Zhu, Jun Wang, Liang Wang, Feifei Tang, Huiqiang Huang, Zhongjun Xia, Liqiong Liu, Danyu Wang, Nan Zhong and 23 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Zhi Guo *Department of Hematology, The Sixth Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China.
Jie Zhu *Institute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Medical College, Wuhan University of Science and Technology, Wuhan, China.
Jun WangDepartment of Hematology, Hongkong University Shenzhen Hospital, Shenzhen, China.
Liang WangDepartment of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Feifei TangDepartment of Hematology, Peking University People's Hospital, Beijing, China.
Huiqiang HuangDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhongjun XiaState Key Laboratory of Oncology in South China, Department of Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Liqiong LiuDepartment of Hematology, The Sixth Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China.
Danyu WangDepartment of Hematology, The Sixth Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China.
Nan ZhongDepartment of Hematology, The Sixth Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China.
Huanhuan ZhouDepartment of Hematology, The Sixth Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China.
Zhaogui ZhouDepartment of Hematology, The Sixth Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China.
Wei DaiDepartment of Hematology, The Sixth Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China.
Xiaojun XuDepartment of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Hao ZhouDepartment of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Lijuan DengKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.
Jingye MengDepartment of Hematology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
Zhiqiang SunDepartment of Hematology, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Liang ShaoDepartment of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Yu J CaoState Key Laboratory of Chemical Oncogenomics, Shenzhen Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, China.
Yansong LiuDepartment of Critical Care Medicine, The Sixth Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China.
Rong QuDepartment of Critical Care Medicine, Huizhou Central People Hospital, Huizhou, China.
Guowei LiDepartment of Hematology, Huizhou Central People Hospital, Huizhou, China.
Peng ChenDepartment of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Hongyan ZhangDepartment of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Jing LiangShandong Key Laboratory of Rheumatic Disease and Translational Medicine, Department of Oncology, Shandong Lung Cancer Institute, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.
Yuhua LiHematology Department, Southern Medical University, Zhujiang Hospital, Guangzhou, China.
Jiajun LiuDepartment of Hematology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Zishan XuDepartment of Hematology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong SAR, China.
Soong Sung IndaDepartment of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong SAR, China.
Xiaochen XiangInstitute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Medical College, Wuhan University of Science and Technology, Wuhan, China.
Qingming WuInstitute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Medical College, Wuhan University of Science and Technology, Wuhan, China.
Qiang WangInstitute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Medical College, Wuhan University of Science and Technology, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intravenous immunoglobulin (IVIG), first developed for the treatment of patients with antibody deficiencies, is now widely used in clinical practice, especially in hematological and immune system diseases, and its application in hematological oncology chemotherapy, cellular immunotherapy and hematopoietic stem cell transplantation (HSCT) is becoming more and more common. The Chinese Collaborative Group for Infection Immunology and Microecology Research Translation Collaborative Group organized relevant experts to discuss and propose the "Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases," which was formulated based on the progress of research on the application of IVIG in blood diseases, and provides a basis for the standardization of the use of IVIG in hematologic disorders.

Indexed as

chimeric antigen receptor T-Cellclinical applicationexpert consensushematologic disordershematopoietic stem cell transplant (HSCT)IVIG

Identifiers

PMID40236459
PMCPMC11996829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.